ASCO Genitourinary Cancers Symposium

Videos

Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.

Sumanta K. Pal, MD, FASCO, on CONTACT-03 Trial and Investigating Targeted Therapy, Immunotherapy for Patients with RCC

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCC

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.

Robert J. Motzer, MD, on Research Areas of Focus in Renal Cell Carcinoma

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC

The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.

Robert J. Motzer, MD, on the Possible Impact of a Phase 3 Trial for Advanced ccRCC

The medical oncologist at Memorial Sloan Kettering Cancer Center highlighted what clinicians treating patients with advanced ccRCC should understand about this trial in progress.

Robert J. Motzer, MD, on a Phase 3 Trial Evaluating MK-6482 Plus Lenvatinib Versus Cabozantinib for Advanced ccRCC

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward

An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCC

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed the significance of the phase 3 CheckMate 9ER study results.

ASCO Genitourinary Cancers Symposium | Conference